Abstract
Hypothesis/Aim Type 1 diabetes (T1D) is associated with excess coronary artery disease (CAD) risk even when known cardiovascular risk factors are accounted for. Genetic perturbation of hematopoiesis that alters leukocyte production is a novel independent modifier of CAD risk. We examined whether there are shared genetic determinants and causal relationships between leukocyte counts, T1D, and CAD.
Methods Genome-wide association studies (GWAS) summary statistics were utilized to perform pairwise linkage disequilibrium score regression (LDSC) and heritability estimation from summary statistics (ρ-HESS) to respectively estimate the genome-wide and local genetic correlations, and two-sample Mendelian randomization (MR) to estimate the causal relationships between leukocyte counts (335 855 healthy subjects), T1D (18 942 cases, 501 638 controls), and CAD (122 733 cases, 424 528 controls).
Results There was significant genome-wide genetic correlation (rg) between T1D and CAD (rg = 0.088; P = 9.0e-03) and both diseases shared significant genome-wide genetic determinants with eosinophil count (rg(T1D) = 0.093, P = 7.20e-03; rg(CAD) = 0.092, P = 3.68e-06) and lymphocyte count (rg(T1D) = −0.052, P = 2.80e-02; rg(CAD) = 0.1761, P = 1.82e-15). Sixteen independent loci showed stringent Bonferroni significant local genetic correlations between leukocyte counts, T1D and/or CAD. Cis-genetic regulation of the expression levels of genes within loci that are shared between T1D and CAD were associated with both diseases as well as leukocyte counts, including SH2B3, CTSH, MORF4L1, CTRB1, CTRB2, CFDP1, and IFIH1. Genetically predicted lymphocyte, neutrophil, and eosinophil counts were associated with T1D and CAD (lymphocyte odds ratio (OR)T1D = 0.667, P = 2.02e-19; ORCAD =1.085, P = 2.67e-06; neutrophil ORT1D = 0.82, P = 5.63e-05; ORCAD = 1.17, P = 5.02e-14; and eosinophil ORT1D: 1.67, P = 4.45e-25; ORCAD: 1.07; P = 2.02e-03).
Conclusions/Interpretations This study sheds light on shared genetic mechanisms that underlie T1D and CAD, which may contribute to their co-occurrence through regulation of gene expression and leukocyte counts. This study also identifies molecular targets for further investigation for disease prediction and potential drug discovery.
What is already known about the subject?
Genetic factors have been shown to contribute to the occurrence of coronary artery disease (CAD) in type 1 diabetes (T1D), but the mechanisms are unknown.
Genetic perturbation of hematopoiesis that alters leukocyte production is associated with CAD risk and clinical observations have documented altered leukocyte counts in T1D. However, it is unknown whether altered leukocyte frequencies contribute to T1D and the co-occurrence of T1D and CAD or these reflect reverse causation.
What is the key question?
Do T1D and CAD share genetic determinants with leukocyte counts, and if so, are genetically predicted leukocyte counts associated with risk of T1D or CAD and their co-occurrence?
What are the new findings?
T1D and CAD share significant genetic architecture, and both diseases share significant genetic determinants with eosinophil and lymphocyte counts.
Genetically predicted eosinophil, lymphocyte, and neutrophil counts are associated with risk of T1D and CAD.
Genetic regulation of the expression levels of genes in shared loci between T1D and CAD are associated with both diseases and leukocyte counts.
How might this impact on clinical practice in the foreseeable future?
Genetic heritability for T1D is shared with CAD risk and leukocyte counts, and the counts of eosinophils, lymphocytes, and neutrophils are associated with both diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JDRF (2-SRA-2022-1276-S-B).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only GWAS summary statistics, which are publicly available and do not require ethical approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The source of publicly available data used for analyses in this study are described in the manuscript. All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- T1D
- Type 1 diabetes
- CAD
- Coronary artery disease
- GWAS
- Genome-wide association studies
- HSPCs
- Hematopoietic stem and progenitor cells
- LD
- Linkage disequilibrium
- LDSC
- Linkage disequilibrium score regression
- p-HESS
- Heritability estimation from summary statistics
- eQTL
- Expression quantitative trait loci
- BAS
- Basophils
- EOS
- Eosinophils
- LYM
- Lymphocytes
- Mon
- Monocytes
- NEU
- Neutrophils
- pQTL
- Protein quantitative trait loci
